Original BioMedicals Co Ltd

Original BioMedicals maintains a strong liquidity position with cash and equivalents of TWD 133.85 million, representing 72.8% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -51.3%, driven by a free cash flow of TWD -94.37 million and operating cash flow of TWD -96.01 million. Despite this, the current ratio of 9.74 indicates robust short-term liquidity. Profitability metrics are negative, with a return on equity of -64.31% and return on assets of -55.19%, reflecting significant operational losses. The company reported a net loss of TWD 101.51 million and an operating loss of TWD 104.59 million, driven by high R&D and development costs typical in the biotechnology sector. The company's revenue is concentrated domestically, with no disclosed international operations. Its product portfolio includes OBM-B01 for cyanide detoxification, OBM-CL for antibiotic treatment, and OBM-A01 for radiation injury prevention. No material revenue concentration by segment is disclosed, but the company's reliance on a few key products increases product-specific risk. Outlook for the current fiscal year shows a continuation of operational losses, with no material revenue growth expected. The company's R&D pipeline includes several preclinical and clinical-stage products, but commercialization timelines remain uncertain. No competitor revenue share data is available for direct comparison. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no near-term debt maturities and maintains a debt-to-equity ratio of 0.07. No dilution sources were identified in recent filings, and shares outstanding remain unchanged between basic and diluted measures. Recent filings include the 2023 annual report, which details ongoing clinical trials for OBM-B01 and OBM-A01. No material regulatory or litigation events were disclosed in the latest 10-K equivalent filing. The company's R&D expenses remain a key focus area, with no material changes in strategic direction.